13May
Member Press Release - New England Biolabs to acquire Fluorogenics Limited
IPSWICH, MA (May 10th, 2021) — New England Biolabs, Inc. (NEB®), a leading supplier of life science reagents, today announces that it has entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB.
With the point-of-care market becoming more focused on the development of robust, accurate and cost-effective diagnostic tests for use outside of traditional hospital and laboratory settings, there is a growing need for reagents that can withstand ambient shipping and storage. Lyophilization is the preferred solution and is a well-established technology across a number of industries, making it desirable from a regulatory and feasibility perspective. NEB currently supplies research use only reagents for further development and validation by its customers in diagnostic assays, and is looking to increase its ability to offer lyophilized reagents.
Read the full Press Release: https://international.neb.com/about-neb/news-and-press-releases/new-england-biolabs-to-acquire-fluorogenics-limited
Related
BIVDA Welcomes Publication of Medtech Funding Mandate BIVDA, the UK trade association for in v...
Read More >
BIVDA Statement on UK Rare Disease Framework BIVDA Chief Executive Doris-Ann Williams has welco...
Read More >
BIVDA is pleased to support Associations Week 2021, an initiative that shines a spotlight on the wor...
Read More >
Please see the below quote from BIVDA regarding exemptions for key workers regarding COVID-19 a...
Read More >
Microsemi CRP LC-767G HORIBA Medical, specialists in automated in vitro diagnostic systems for ...
Read More >
Commenting on the result of the General Election, BIVDA’s Chief Executive Doris-Ann Williams MBE sa...
Read More >